LYTIX — Lytix Biopharma AS Balance Sheet
0.000.00%
Last trade - 00:00
- NOK268.06m
- NOK217.52m
- NOK3.99m
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | NAS | NAS | NAS | NAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12.8 | 28.4 | 197 | 145 | 50.5 |
Net Total Receivables | 4.64 | 4.17 | 5.68 | 6.74 | 12.8 |
Total Other Current Assets | |||||
Total Current Assets | 17.4 | 32.6 | 203 | 152 | 63.3 |
Net Property, Plant And Equipment | — | — | — | 0.124 | 0.11 |
Total Assets | 17.4 | 32.6 | 203 | 152 | 63.4 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.85 | 12.7 | 13.3 | 16.9 | 12.1 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 3.85 | 12.7 | 13.3 | 16.9 | 12.1 |
Common Stock | |||||
Additional Paid In Capital | |||||
Total Equity | 13.6 | 19.9 | 190 | 135 | 51.4 |
Total Liabilities & Shareholders' Equity | 17.4 | 32.6 | 203 | 152 | 63.4 |
Total Common Shares Outstanding |